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The randomized play-the-winner (RPW) rule is very useful in clinical trials for
patient allocation with two treatments. L. J. Wei (1979, Ann. Statist. 7, 291296)
introduces the generalized Friedman’s urn (GFU) model to clinical trials of K treat-
ments (as an extension of the RPW). In this paper, we propose a new adaptive
design for multi-arm clinical trials. The proposed adaptive design proportionally
depends on the success rates of each treatment, so that a treatment which is doing
well is more likely to be assigned in future trials than a treatment which is doing
poorly. The new design is more reasonable although it is no longer a GFU model.
In the paper we show that the new design has some desirable asymptotic properties
and that it has wider and easier applications in practice. Some simulations also
support this new design.  2001 Elsevier Science (USA)
AMS 1991 subject classification: 62G10.
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1. INTRODUCTION
Traditional statistical designs for multi-arm clinical trials strive for a
balanced allocation of patients to treatments. This is done to minimize the
variance of different estimators. However, from an ethical perspective, the
balanced allocation may be undesirable, especially when the failure out-
comes are rather serious. In this case, it is desirable to have designs which
reduce the total number of failure outcomes in a trial while at the same
time preserving the capability of making a comparison between treatments.
Adaptive designs attempt to capture some type of balance between these
two competing issues.
One important family of adaptive designs is the generalized Friedman’s
urn (GFU) model (GFU is also named as generalized Polya urn (GPU)
in the literature). The model can be described as follows. Consider an urn
containing K types of particles, representing K ‘‘treatments.’’ The patients
are to be allocated sequentially to the treatments in n stages. At the begin-
ning, the urn contains Y0=(Y0, 1 , Y0, 2 , ..., Y0, K) particles, where Y0, k
denotes the number of the particles of type k, k=1, ..., K. At the stage i,
a particle is drawn or split at random from the urn and returned. When a
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type k particle is drawn, the treatment k is then assigned to the i th patient,
k=1, ..., K. After observing a random variable !ki which may be considered
as the response of the kth treatment at the i th stage, is observed, additional
Di (k, j, !ki ) particles of type j, j=1, ..., K, are added to the urn, where
Di (k, j, !ki ) is a function of the random variable !
k
i . This makes the model
more appropriate for adaptive designs.
Define the matrix Ei=[E(D i (k, j, !ki ) | Fi&1), k, j=1, ..., K] , where the
sigma field Fi is generated by [Y0 , Y1 , ..., Yi]. When Ei #E for all i, the
model is called homogeneous and otherwise non-homogeneous. In the
sequel, we refer to the matrix D i=[Di (k, j, !ki ), k, j=1, ..., K] as the rule
and Ei as the generating matrix at the i th stage. After n splits and genera-
tions, the urn composition is denoted by the vector Yn=(Yn, 1 , Yn, 2 , ...,
Yn, K), where Yn, k represents the number of particles in the urn of type k
after the n th stage.
The GFU model has biostatistical applications to clinical trials (Wei,
1979), bioassay (Rosenberger et al. 1997), and psychophysics (Rosenberger
and Grill, 1997, Hu and Rosenberger, 2000), etc. A general review can be
found in Rosenberger (1996).
For the non-homogeneous models, it is usually assumed that Ei  E (see
Hu and Rosenberger, 2000). In both cases, under general conditions (say,
irreducible and aperiodic) the matrix E has a unique maximal eigenvalue \1
in magnitude which is positive and corresponds to a nonnegative left eigen-
vector v=(v1 , v2 , ..., vK) with Kk=1 vk=1. The eigenvector v consists of
important quantities in limiting results for adaptive designs associated with E.
For a homogeneous generating matrix E, general discussions on the asymptotic
theory can be found in Athreya and Karlin (1968), Athreya and Ney (1972),
Smythe (1996) and Bai and Hu (1999). Besides, Bai and Hu (1999) also
investigate the asymptotic theory for nonhomogeneous models.
Wei (1979) discusses GFU with applications to clinical trials of K treat-
ments. In the GFU model considered by him, a success on treatment k
generates a particle of type k, and a failure on treatment k generates
1(K&1) particles of each of the other K&1 types. However, it doesn’t
seem adaptive to equally add 1(K&1) particles of other K&1 types to the
urn when a failure on treatment k is met. In fact, if one treatment performs
extremely poorly, then it is unreasonable to add the same number of par-
ticles of that type to the urn. Li (1995) proposes a design that only
generates particles of the type of the success, and adds nothing to the
failures. This leads to a diagonal generating matrix. Andersen et al. (1994)
discuss an urn scheme where a success on treatment k generates a type k
particle, and a failure generates particles of the other K&1 types, propor-
tionally to the urn composition at the previous stage. They claim that the
theoretical results might be difficult to obtain because the generating
matrix is random and dependent on all previous splits and generations.
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In this paper, we propose a new adaptive design in Section 2. The new
adding scheme generates one particle of type k for a success of treatment
k, and for a failure of the treatment k, it generates particles of the other
K&1 types proportional to the previous success rates of the K&1 treat-
ments. Though this design is no longer a GFU, it provides a more logical
and attractive allocation rule. For the new design, the generating matrices
are nonhomogeneous and the random functions are dependent on all pre-
vious splits and generations. The new adaptive design seems similar to the
one proposed by Andersen et al. (1994). However, the asymptotics for the
new design are not as difficult to establish as claimed by Andersen et al. (1994).
In Section 3, we shall establish some desirable asymptotic properties of this
design which are important for statistical inference. In Section 4, we report
some preliminary simulations. These simulations support the new design.
2. A NEW ADAPTIVE DESIGN FOR MULTI-ARM
CLINICAL TRIALS
One application of the GFU model is the randomized play-the-winner
(RPW) rule, which was introduced by Wei and Durham (1978) as an
extension to Zelen’s (1969) play-the-winner rule. Wei (1979) noted that the
RPW rule could be formulated as a GFU model. Suppose that there are
two treatments (say, TA and TB) in the study and that the responses are
dichotomous (i.e. success or failure [S and F]). We start with Y0=(:, :)
particles in the urn. If a type 1 split occurs, the patient is assigned to treat-
ment TA and otherwise, the patient is assigned to treatment TB . Then, the
particle is returned to the urn and the patient response is observed. A
success on TA or a failure on TB generates a type 1 particle; a success on
TB or a failure on TA generates a type 2 particle.
Under the simple population model p1=P[S | TA], p2=P[S | TB],
q1=1& p1 , q2=1& p2 , it is easy to see that we have a GFU with
E=\p1q2
q1
p2+ .
According to Athreya and Karlin (1968), the proportion of patients
assigned to each treatment and the proportions of each type of particle are
asymptotically equal to each other, i.e.,
Nn, 1
n

q2
q2+q1
and
Yn, 1
Yn, 1+Yn, 2

q2
q2+q1
almost surely (a.s.)
as n  , where Nn, 1 denotes the number of times that the treatment 1 is
selected in the first n splits.
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Wei (1979) discussed the following GFU with applications to clinical
trials of K treatments (as an extension of the RPW of two treatments).
Adaptive Design 1 (GFU Model 1, Wei, 1979). Starting from Y0=
(Y0, 1 , ..., Y0, K), when a type k splits (randomly from the urn), we assign the
patient to the treatment k and observe the patient’s response. A success on
treatment k adds a particle of type k to the urn and a failure on treatment k adds
1(K&1) particles for each of the other K&1 types. Let X kj =1 if the jth split
is type k, and 0 otherwise. Let Tj=1 if the response of the jth trial is a success,
0 otherwise. Define pk #P[Tj=1 | X kj =1], for j=1, 2, ..., n, k=1, 2, ..., K,
and define P#[ p1 , p2 , ..., pK]. Let qk #1& pk as usual. We have a GFU with
E(1)=\
p1 (K&1)&1 q1 } } } (K&1)&1 q1
+ .(K&1)&1 q2 p2 } } } (K&1)&1 q2} } } } } } } } } } } }(K&1)&1 qK (K&1)&1 qK } } } pK
It follows from Athreya and Karlin (1968) that
lim
n  
Yn, k
K:+n
 v (1)k a.s.,
where v (1)k =1qk 
K
j=1 1qj is the kth element of the left eigenvector corre-
sponding to the largest eigenvalue \1=1 of E(1).
When there is a failure on treatment k, it should be more reasonable to
add more articles corresponding to better treatment among the other K&1
treatments. Thus, the following adaptive design is proposed.
Adaptive Design 2 (GFU Model 2). If the success probabilities of treat-
ments were known, while one particle of the same type is added to the urn,
it seems more reasonable to add fractional particles for the other K&1
types, proportional to the success rates P, i.e., to add pj  (Kh=1 ph& pk)
particles of type j to the urn, for j{k, when the response is a failure on
treatment k. Define M= pk , we have a GFU with the generating matrix
E(2)=\
p1
p2
M& p1
q1 } } }
pK
M& p1
q1
+p1M& p2 q2 p2 } } } pKM& p2 q2} } } } } } } } } } } }p1
M& pK
qK
p2
M& pK
qK } } } pK
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Results of Athreya and Karlin (1967, 1968) yield
lim
n  
Yn, k
a0+n
 v (2)k and lim
n  
Nn, k
n
 v (2)k a.s.,
where v (2)k = pk q
&1
k (M& pk)
K
j=1 p jq
&1
j (M& pj) is the k th element of
the left eigenvector corresponding to the largest eigenvalue of E(2) and
a0=Kk=1 Y0, k .
However, the GFU model 2 is not realistic since P=( p1 , ..., pK) is in fact
unknown. But it gives an idea to improve the adaptive design. We now
propose the following adaptive design which is more realistic and easy to
implement. To clearly describe the new design, we introduce some notation.
Write Nn=(Nn, 1 , ..., Nn, K) and Sn=(Sn, 1 , ..., Sn, K), where Nn, k denotes the
number of times that the k th treatment is selected in the first n splits, and
Sn, k denotes the number of successes of the k th treatment in the Nn, k trials,
k=1, ..., K. Define Rn=(Rn, 1 , ..., Rn, K), where Rn, k=(Sn, k+1)(Nn, k+1),
k=1, ..., K. Here, adding 1 in both the numerator and denominator does
not affect our asymptotic results, it is only for avoiding the nonsense case
of 00. It is easy to see that N0=(0, ..., 0), S0=(0, ..., 0) and, R0=(1, ..., 1).
Based on Rn , an estimation of P, we have the following design:
Adaptive Design 3 (The Proposed Model). At the nth stage, if the
response is a success on the treatment k, then add one particle of type k.
And if it is a failure, then add Rn&1, j (Mn&1&Rn&1, k) particles of type j
to the urn for all j{k, where Mn&1=Kj=1 Rn&1, j .
Note that the new design is no longer a GFU model since the expected
increment of particles of each type is different from stage to stage. The con-
ditionally expected increment of the particles of the n th step given the
Rn&1, k ’s is
En=\
p1
Rn&1, 2
Mn&1&Rn&1, 1
q1 } } }
Rn&1, K
Mn&1&Rn&1, 1
q1
+Rn&1, 1Mn&1&Rn&1, 2 q2 p2 } } } Rn&1, KMn&1&Rn&1, 2 q2} } } } } } } } } } } }Rn&1, 1
Mn&1&Rn&1, K
qK
Rn&1, 2
Mn&1&Rn&1, K
qK } } } pK
Comparing the above three adaptive designs, the following three points
are easily seen.
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(i) When K=2, the Adaptive Designs 1, 2, and 3 are all the RPW
rule. So all of these designs are extensions of RPW rule to K treatments.
(ii) For Designs 1 and 2, when K>2, notice that for any k{ j,
1k, jK, if pk>pj , we have
v (2)k
v (2)j
&
v (1)k
v (1)j
=
( pk qk )(M& pk)
( pj q j )(M& pj)
&
1qk
1qj
=
(1qk )( pk& pj)(M& pk& p j)
( pj q j ) h{ j ph
>0.
GFU model 2 is more ethical than GFU model 1, because more patients
will be assigned to a better treatment in GFU model 2 than those in GFU
model 1.
(iii) For the adaptive design 3, the generating matrix En differs for
each n and depends on all previous splits and generations. The asymptotic
theorems of Athreya and Karlin (1968), Smythe (1996), and Bai and Hu
(1999) do not apply here.
3. ASYMPTOTIC PROPERTIES
Using the notation defined in the last section, we shall establish the
following results.
Theorem 1. For the adaptive design 3 proposed in Section 2, if
0<pk<1, k=1, ..., K, then
lim
n  
Yn, k
K:+n
 v (2)k and lim
n  
Nn, k
n
 v (2)k a.s.,
where
v (2)k =
pk
qk
(M& pk)
:
K
j=1
pj
qj
(M& pj)
is the kth element of the left eigenvector corresponding to the largest eigen-
value \1=1 of E(2).
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In the proof of Theorem 1, one can easily see that Sn, k is a sum of
independent and identically distributed (iid) random variables with ran-
dom number of terms and that Rn, k is a consistent estimator of pk . As a
by-product, we have the following corollary.
Corollary 2. Under the conditions of Theorem 1, we have
- n (Rn&P)  N(0, diag[ p1 q1 v (2)1 , ..., pK qKv (2)K ]).
Note. In Corollary 2, if the allocation Nn is defined by stopping times
{ki other than those as in Adaptive Design 3, the conclusion of Corollary
2 remains true provided that the trial responses Tn=(T 1n , ..., T
K
n ) are an iid
sequence of K vectors of independent Bernoulli trials, where the vector v(2)
should be redefined as the limit of Nn n and Tn is defined later prior to the
proof of Lemma 1. Note that the first task of clinic trials is to detect the
best treatment as fast as possible and the ethical perspective is only the
second. Therefore, if the experimenter over-emphasizes the success rates,
then success rates of some treatment cannot be well estimated due to less
allocation of patients.
Now, we return to our proofs of the main results. At first, we give
a mathematical description of the Adaptive Design 3. Without loss of
generality, we assume that Y0=(:, ..., :), N0=(0, ..., 0) and S0=(S0, 1 , ...,
S0, K)=(0, ..., 0). Define Xj=(X 1j , ..., X
K
j ) to be the indicator of the selec-
tion of the treatments, that is, X kj =1 if the jth split is of type k, and 0
otherwise. Note that for each j, there is one and only one k such that
Xkj =1. The conditional distribution of Xj given Yj&1 is multinomial, that
is, P(X kj =1 | Yj&1)=Yj&1, k (K:+ j&1). Then, we define a success
indicator as follows: Let [[T kj , j=1, 2, ...], k=1, 2, ..., K] be K inde-
pendent sequences of iid Bernoulli trials where the success probability for T kj
is pk , k=1, ..., K. We use T kj =1 to indicate the event that the response of
the kth treatment in the jth trial is a success, and 0 for the failure. Note that
we shall only use the product X kj T
k
j . Therefore, when X
k
j =1, T
k
j represent
the response of the k th treatment in the j th trial. When X kj =0, T
k
j does
not appear in our statistics. Thus, it can be considered as an imaginary
variable or whatever else, without affect to our problems. (Comparing with
the notation defined in Section 2, our T kj is a random variable distributed
according to the conditional distribution of Tj given X kj =1.)
Then, Nj, k=Nj&1, k+X kj and S j, k=S j&1, k+X
k
j T
k
j . By the adding rule,
when X kj =1, we add T
k
j particles of type k and (1&T
k
j ) R j&1, l 
(Mj&1, k&Rj&1, k) particles of type l to the urn, l{k. Note that as X kj =1
which implies X lj =0 for all l{k, we may rewrite the adding rule as adding
Xkj T
k
j +l{k X
l
j (1&T
k
j ) Rj&1, l (Mj&1, k&Rj&1, k) particles of type k to
the urn. Write
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Dj=\
T 1j
R j&1, 2 (1&T 1j )
Mj&1, 1&Rj&1, 1
} } }
Rj&1, K (1&T 1j )
M j&1, 1&Rj&1, 1
+ .Rj&1, 1 (1&T
2
j )
Mj&1, 2&Rj&1, 2
T 2j } } }
Rj&1, K (1&T 2j )
Mj&1, 2&Rj&1, 2
} } } } } } } } } } } }
Rj&1, 1 (1&T Kj )
Mj&1, K&Rj&1, K
Rj&1, 2 (1&T Kj )
Mj&1, K&Rj&1, K
} } } T Kj
Then, we have the recursive formula
Yj=Yj&1+XjD j .
Define
F$j=_[X k1 , ..., X
k
j , T
k
1 , ..., T
k
j&1 : 1kK]
and
Fj=_[X k1 , ..., X
k
j , T
k
1 , ..., T
k
j : 1kK].
It is trivial that Tj=(T 1j , ..., T
K
j ) is independent of F$j and Y j # Fj .
Before processing with the proofs of Theorem 1, we first establish the
following preliminary results.
Lemma 1. Rn, k  pk , a.s. \1kK.
Proof. Using the notation introduced above, we have Nn, k=nj=1 X
k
j .
We first show that Nn, k  , a.s. \1kK.
Define the event An, k=[X kn=1], for k=1, 2, ..., K and n1. Then,
:
n
P(An, k | Fn&1)=:
n
Yn&1, k
K:+n&1
:
n
:
K:+n&1
=+. (1)
By the generalized BorelCantelli lemmas (see, e.g., Chow and Teicher,
1997, p. 249), it follows from (1) that
P[An, k , i.o.]=1,
which simply implies that,
Nn, k  + a.s.
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Define {ki =min[ j; N
k
j =i], k=1, ..., K and i=1, 2, ... . For each fixed k,
{ki is the i th arrival time of the k th treatment. Note that [{
k
i , i=1, 2, ...]
is a sequence of strictly increasing stopping times with respect to the _-field
sequence [F$n]. Let 3ki =T
k
{ ki
. For any i1< } } } <it , we have
P(3ki1= } } } =3
k
it
=1)
= :
j1< } } } <jt
P(T kj1= } } } =T
k
jt
=1, {ki1= j1 , ..., {
k
it
= jt)
= :
j1< } } } <jt
P(T kjt=1) P(T
k
j1
= } } } =T kjt&1=1, {
k
i1
= j1 , ..., {kit= jt)
=pk :
j1< } } } <jt&1
P(T kj1= } } } =T
k
jt&1
=1, {ki1= j1 , ..., {
k
it&1
= jt&1)
=ptk .
This shows that [3k1 , 3
k
2 , ...] is an iid sequence of Bernoulli trials with
success probability pk . By the Strong Law of Large Numbers, we have
3 kn=n
&1 ni=1 3
k
i  pk , a.s.
By the facts that
Sn, k Nn, k=3 kNn, k , and Nn, k  , a.s.,
we conclude that Sn, kNn, k  pk , a.s. Then, the proof of Lemma 1 is
complete.
Remark on the Proof of Corollary 2. Using the notation of Lemma 1,
for a set of constants [%kik , ik=1, 2, ..., mk , k=1, ..., K] taking values in
[0, 1], we have
P \ ,
K
k=1
,
mk
ik=1
[3kik=%
k
ik
]+
= :
C(k)
P \ ,
K
k=1
,
mk
ik=1
[T kj kik
=%kik , {
k
ik
= j kik]+
= ‘
K
k=1
‘
mk
ik=1
p%
k
ik
k q
1&%
k
ik
k :
C(k)
P \ ,
K
k=1
,
mk
ik=1
[{kik= j
k
ik
]+
= ‘
K
k=1
‘
mk
ik=1
p%
k
ik
k q
1&%
k
ik
k ,
where C(k) denote all possibilities of integers that the stopping times
[{kik , 1ikmk , k1K] may take, that is,
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(i) 1 j k1<j
k
2< } } } <j
k
mk
, 1kmk ;
(ii) there do not exist four integers 1k1<k2K and 1i1mk1 ,
1i2mk2 , such that j
k1
i1
= j k2i2 .
The above equations show that the random variables [3 ki , i=1, 2, ...;
k=1, 2, ..., K] are mutually independent. Therefore,
_n&12k :
nk
i=1
(3 ki & pk), k=1, ..., K& N(0, diag[ p1 q1 , ..., pK qK]) ,
provided that min(n1 , ..., nK)  .
Using the conclusion of Theorem 1 and the dominated convergence
theorem,
E exp [- n [iu1 (Rn, 1& p1)+ } } } +iuK (Rn, K& pK)]]
=E ‘
K
k=1 _qk+ pk exp \
iuk - n
Nn, k +&
Nn, k
e&iuk - npk
 ‘
K
k=1
exp _&12 u2k pkqk v (2)k & .
This proves Corollary 2.
Lemma 2. If 0<pk<1, \k=1, 2, ..., K, then
0<lim inf
n  
Nn, k
n
lim sup
n  
Nn, k
n
<1 a.s. for all k=1, 2, ..., K.
Proof. We first show that \k, Yn, k   a.s. with the same order of n.
Now, define Zn, k=(Yn, k&Yn&1, k)&E((Yn, k&Yn&1, k) | Fn&1) which
forms a martingale difference sequence for n=1, 2, ... and fixed k. By the
fact that |Yn, k&Yn&1, k |1, we have
:

n=1
1
n2
EZ 2n, k :

n, k
4
n2
<,
which implies (see Theorem 2.18 on p. 35 of Hall and Heyde, 1980) that
1
n
:
n
j=1
Zj, k  0, a.s.
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By noting E(Dn | F$n)=En # Fn&1 and E(Xn | Fn&1)=Yn&1 (K:+n&1),
the above limit is equivalent to
1
n
Yn&
1
n
:
n
j=1
Yj&1
K:+ j&1
Ej  0, a.s.
By Lemma 1 (Rn, k  pk a.s.), En&E(2)  0, a.s. Thus, we obtain
1
n
Yn&
1
n
:
n
j=1
Yj&1E
(2)
K:+ j&1
 0, a.s.
The k th component of the second term in the above limit is
1
n
:
n
j=1 \
Yj&1, k
K:+ j&1
pk+ :
h{k
Y j&1, h
K:+ j&1
qhpk
M&qh+$k ,
where $k= pk min[1, qh (M&qh), h{k]>0. In the proof of the last
inequality, we have used the fact that for each j, Kh=1 Yj&1, h=K:+ j&1.
This proves our assertion, that is,
lim inf
n  
Yn, k
n
$k>0, a.s. (2)
A dual consequence of the above is that
lim sup
n  
Yn, k
n
<1, a.s. (3)
Similarly define Z $n, k=X
k
n&E(X
k
n | Fn&1). Then by the fact that
|Z $n, k |1, we can similarly show that
1
n
Nn, k&
1
n
:
n
j=1
E(X kj | Fj&1)  0 a.s.,
which implies
1
n
Nn, k&
1
n
:
n
j=1
Y j&1, k
K:+ j&1
 0 a.s. (4)
Together with (2) and (3), we have
0<lim inf
n  
Yn, k
n
lim inf
n  
Nn, k
n
lim sup
n  
Nn, k
n
lim sup
n  
Yn, k
n
<1 a.s.
This finishes the proof of Lemma 2.
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Lemma 3. If 0<pk<1, k=1, ..., K, then
lim sup
n  
- nlog log n &En&E(2)&<, a.s.,
where the matrix norm &A& is the maximum absolute value of the entries
of A.
Proof. Recall the proof of Lemma 1. By the Law of Iterated Logarithm,
we have 3 kn& pk=Oa.s. (- log log nn). Again using the relation Sn, kNn, k
=3 kNn, k and applying Lemma 2, we have, for each k=1, ..., K,
lim sup
n  
- nlog log n |Rn, k& pk |<, a.s.,
from which the lemma follows.
Lemma 4 (Burkholder, 1973). Let [Yn] be a complex martingale dif-
ference sequence with respect to the increasing _-field [Fn]. Then for p>1
E } :
n
i=1
Yi }
p
C( p) E \ :
n
i=1
|Y i |2+
p2
.
In the sequel, for convenience of notation, without loss of generality, we
only give the proofs of Theorem 1 for the case K=3 in the following
discussion. Now, the generating matrix is then
p1
Rn&1, 2
Rn&1, 2+Rn&1, 3
q1
Rn&1, 3
Rn&1, 2+Rn&1, 3
q1
En=\ Rn&1, 1Rn&1, 1+Rn&1, 3 q2 p2 Rn&1, 3Rn&1, 1+Rn&1, 3 q2+ ,Rn&1, 1
Rn&1, 1+Rn&1, 2
q3
Rn&1, 2
Rn&1, 1+Rn&1, 2
q3 p3
and
E(Yn | Fn&1)=Yn&1 \I+ 13:+n&1 En+ ,
where
Fn=_[X kj , Tj : jn, 1k3].
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Let [Y (2)n , n=0, 1, 2, ..., ] be the process of particles composition in the
urn of GFU Model 2 which starts with Y (2)0 =(:, :, :). Then we have
p1
p2
p2+ p3
q1
p3
p2+ p3
q1
E(2)=\ p1p1+ p3 q2 p2 p3p1+ p3 q2+ .p1
p1+ p2
q3
p2
p1+ p2
q3 p3
Proof of Theorem 1. We only need to prove the first conclusion of the
theorem, since the second is a consequence of (4) and the first conclusion
of the theorem. From the definition of the Adaptive Design 3, we have
Yn=Yn&1+Xn Dn
=Yn&1 \I+ En3:+n&1++Qn
=Yn&1 Wn&1+
Yn&1 (En&E
(2))
3:+n&1
+Qn , (5)
where Qn=XnDn&Yn&1En (3:+n&1) and Wn&1=I+E(2)(3:+n&1).
Repeating the process (5), we have
Yn=Y0 W0 } } } Wn&1
+ :
n
j=1
1
3:+ j&1
Yj&1(Ej&E
(2)) W j } } } Wn&1
+ :
n
j=1
QjWj } } } Wn&1
=(I )+(II )+(III ). (6)
The proof of the theorem will be complete if one can show that
(3:+n)&1 (I )  (v(2))$, (3:+n)&1 (II )  0,
and
(3:+n)&1 (III )  0 a.s.
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Before proceeding with our proofs, we first look into the asymptotic
behavior of the matrices Wi } } } Wn&1 . Write the Jordan decomposition of
the matrix E(2) as
E(2)=P \10
0
J (2)+ P&1,
where
J(2)=\\20
0
\3+ , or \
\2
0
1
\2+ ,
P=(1$ b u$2 b u$3) and P&1=((v(2))$ b v$2 b v$3)$.
Noticing that Wj=I+E
(2)(3:+ j ), we have
Wi } } } Wn&1=P \
3:+n
3:+i
0
1
‘
n
j=i+1 _I+
J(2)
3:+ j&1&+ P&1. (7)
It is not difficult to verify that for both choices of J(2),
‘
n
j=i+1 _I+
J (2)
3:+ j&1&=O((n(i+1))\),
where \=max[ |\2 |, |\3 |]<1.
Therefore, we have
(3:+n)&1 (I )=Y0P \
1
3:
0 + P&1  (1, 0, 0) P&1=(v(2))$.0 O(n \&1)
We now prove (3:+n)&1 (III )  0 a.s. Note that (III) is a sum of
martingale differences. Thus, by the Burkholder inequality, by choosing
m>2(1&\), we have
E " (3:+n)&1 :
n
i=1
Q iW i } } } Wn&1"
m
C(m) n&mE \ :
n
i=1
&Qi Wi } } } Wn&1&2+
m2
(8)
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Note that
" Yi&13:+i&1"1
and, by Qj 1=Xj Dj1&Yj&1Ej1(3:+ j&1)=1&1=0,
&Qi Wi } } } Wn&1&="Q iP \
3:+n
3:+i
0 + P&1"0 O((ni )\))
&(0, O((ni )\), O((ni )) P&1&=O((ni ) \).
Therefore, we obtain from (8)
E " (3:+n)&1 :
n
i=1
Q iWi } } } Wn&1"
m
C(m) n&m \ :
n
i=1
O((ni )2\+
m2
O(n&(1&\) m), if 12<\<1,
={O(n&m2 logm2n), if \=12,O(n&m2) if 0\<12.
The right hand side is summable and hence the assertion that (3:+n)&1
(III )  0 a.s. is proved.
By Lemma 3 and the fact that (Ei&E
(2)) 1=0, we have
(3:+n)&1 &(II )&
n&1 " :ni=1 Yi&13:+i&1 (Ei&E(2)) P \
3:+n
3:+i
0 + P&1"0 O((ni ) \)
n&1 :
n
i=1 " (E i&E
(2)) P \00
0
O((ni )\)+ P&1"
n\&1 :
n
i=1
o(i&13&\)=o(n&min(13, 1&\) log n). (9)
This proves that (3:+n)&1 (II )  0 a.s. and consequently, the proof of the
theorem is complete.
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Some concluding comments should be noted:
(i) From Theorem 1, Adaptive Design 3 has the same asymptotic
limits as Adaptive Design 2. The expected survival probability (asymptoti-
cally) of Adaptive Designs 2 and 3 is
:
K
k=1
pkv (2)k =_ :
K
k=1
pk
qk
(M& pk)&
&1
:
K
k=1
p2k
qk
(M& pk),
while it is
:
K
k=1
pk v (1)k =_ :
K
k=1
1
qk&
&1
:
K
k=1
pk
qk
for the design 1. Simple calculation yields the difference,
_ :
K
k=1
pk
qk
(M& pk)&
&1
_ :
K
k=1
1
qk&
&1
:
k{l
( pk& pl)2 (M& pk& p l)
qkq l
>0.
Thus, patients in the adaptive designs 2 and 3 have a better chance to
survive than in Adaptive Design 1.
(ii) Theorem 1 says that the number of patients of each treatment is
about v (2)k n almost surely. This result ensures that the statistical results of
Rosenberger et al. (1997) and Rosenberger and Sriram (1997) are still true,
when we use the adaptive design 3. For example, the results of Theorems
1, 2, 3 and 4 in Rosenberger and Sriram (1997) are still applicable for
Adaptive Design 3, although it is not a GFU model.
4. A SIMULATED COMPARISON OF THREE DESIGNS
In order to demonstrate the performance of the new design, some
simulations are conducted to compare the three designs: (i) design A: Wei’s
GFU model (GFU model 1); (ii) design B: the design proposed by Andersen,
Faries and Tamura (1994); and (iii) design C: the Adaptive Design 3. We
compare patient allocation numbers and the average success probability
among the three designs.
We consider four treatments and two different starting urn configura-
tions, :=1 and :=5 in the simulation. The total number of patients
(sample size) n=100 is used in the simulation. 10000 replications of each
situation were run in S-Plus (version 4.0). The result of Table I is based on
n=100, :=5 and P=(.3, .5, .5, .7) and (.1, .1., .1, .7), respectively. Table II
is the same as Table I except :=1.
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TABLE I
The Average Allocation Numbers (Standard Deviation) and Average Successes
(Standard Deviation) of the Three Designs
Probability (.3, .5, .5, .7) (.1, .1., .1, .7)
Designs A B C A B C
Allocation
Treatment 1 20 (5.0) 19 (5.4) 19 (5.4) 21 (4.2) 20 (4.4) 18 (4.4)
Treatment 2 25 (6.2) 24 (7.0) 24 (6.8) 21 (4.2) 19 (4.3) 18 (4.3)
Treatment 3 25 (6.2) 25 (7.0) 24 (6.8) 21 (4.2) 19 (4.3) 18 (4.3)
Treatment 4 30 (7.5) 32 (8.5) 33 (8.0) 37 (6.9) 42 (7.4) 46 (6.6)
Success number 52 (5.3) 53 (5.3) 53 (5.2) 32 (5.9) 35 (6.3) 38 (5.9)
Note. n=100, :=5, and P=(.3, .5, .5, .7) and (.1, .1, .1, .7), respectively.
It is clear that both designs B and C perform better than the design A
in term of success outcomes. At the same time, both designs B and C give
quite balanced allocation numbers to each treatment. When the success
probabilities of the treatments are similar, designs B and C provide similar
results. When the success probabilities of the treatments are very different,
the design C provides better results than design B for the case :=5.
From the standard deviation of the allocation numbers and the success
numbers, we find that designs A and C have smaller standard deviation
than design B. With the starting configuration :=1, the allocation number
drifts faster for the better treatment, but the standard deviation tends to be
larger. The design B has the largest standard deviation. Simulations for
n=50 were also conducted in our study and the results are very similar as
those in Tables I and II.
TABLE II
The Average Allocation Numbers (Standard Deviation) and Average Successes
(Standard Deviation) of the Three Designs
Probability (.3, .5, .5, .7) (.1, .1., .1, .7)
Designs A B C A B C
Allocation
Treatment 1 18 (5.7) 15 (7.3) 16 (6.3) 19 (4.5) 16 (5.2) 16 (4.7)
Treatment 2 25 (8.0) 24 (11) 24 (8.8) 19 (4.6) 15 (5.2) 16 (4.7)
Treatment 3 24 (7.9) 24 (11) 23 (8.8) 19 (4.6) 15 (5.2) 15 (4.7)
Treatment 4 34 (10) 37 (14) 37 (11) 43 (9.1) 54 (10) 53 (8.2)
Success number 53 (5.6) 54 (6.0) 54 (5.6) 36 (7.3) 42 (8.0) 42 (6.9)
Note. n=100, :=1, and P=(.3, .5, .5, .7) and (.1, .1., .1, .7), respectively.
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